CTI Biopharma

Acquired

Developing novel therapies for rare blood-related cancers

Founded 1991 · $50.7M raised

Biopharmaceutical
blood cancers
Employees
51–200
Founded
1991
Business Model
B2B
Total Funding
$50.7M
Last Round
$50.7M Corporate RoundJan 2025
Rounds
1
Acquisition Date
May 2023

About

CTI BioPharma Corp was a biopharmaceutical company focused on acquiring, developing, and commercializing novel targeted therapies for blood-related cancers with unmet medical needs. The company's primary commercial product was Vonjo (pacritinib), approved by the FDA in 2022 for the treatment of adults with intermediate or high-risk myelofibrosis. Founded in 1991 and headquartered in Seattle, Washington, CTI BioPharma was listed on NASDAQ (CTIC) until its acquisition by Swedish Orphan Biovitrum AB (Sobi) in June 2023 for approximately $1.7 billion.

Summary

CTI Biopharma is a Biopharmaceutical company, founded in 1991. It has raised $50.7M in total across 1 round, most recently a $50.7M Corporate Round round in Jan 2025. Investors include DRI Healthcare Trust and New Enterprise Associates.

Funding History

Corporate RoundCorporate RoundJan 2025
$50.7M

Sign up to see all 4 rounds

IPO through Corporate Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CTI Biopharma on Indexed.vc
<a href="https://indexed.vc/companies/cti-biopharma"><img src="https://indexed.vc/api/badge/company/cti-biopharma" alt="CTI Biopharma on Indexed.vc" width="260" height="76" /></a>